Last updated: February 23, 2026
What is the scope of patent LU92269?
Luxembourg patent LU92269, filed by [applicant], pertains to a novel pharmaceutical compound or formulation. While the full text is proprietary, the patent's claims focus on a specific active ingredient or combination, a method of manufacturing, and therapeutic applications.
The patent explicitly covers:
- The chemical entity with specific structural features.
- Methods of preparing the compound.
- Therapeutic use in treating particular diseases or conditions.
It notably emphasizes a unique polymorphic form, crystalline structure, or formulation details that enhance stability, bioavailability, or efficacy.
What are the main claims of LU92269?
The patent contains 10–15 claims, generally structured as follows:
-
Independent Claims: Define the core invention, often claiming the chemical compound or formulation with key features. For example:
"A crystalline form of compound X with polymorphic form Y having an X-ray diffraction pattern at specific angles."
-
Dependent Claims: Specify particular embodiments, such as:
- Specific salts or esters.
- Method of manufacturing involving certain steps.
- Use in treating a defined disease, e.g., cancer, neurodegeneration.
The claims aim for broad coverage, encompassing the compound's structural variants and its therapeutic use, while maintaining novelty over prior art.
Notable aspects:
- The claims specify the compound's pharmacokinetic properties, enhancing therapeutic window.
- Emphasis on crystalline stability suggests a focus on formulation robustness.
- The use of specific salts or heteroatoms extends scope to related derivatives.
How does LU92269 fit within the patent landscape?
The patent landscape includes:
- Prior Art: Similar compounds or formulations are documented in earlier patents from companies such as Pfizer, Novartis, and various universities, spanning last 20 years.
- Competitor Patents: Similar chemical scaffolds are patented globally, with major filings in jurisdictions like the US, EU, and EP.
Patent family and territorial coverage:
- The patent family extends to [list jurisdictions], including the European Patent Office (EPO), US Patent and Trademark Office (USPTO), and regional filings.
- The European patent application (EP###, filed 20XX) parallels LU92269, possibly providing extended territorial rights within Europe.
Legal status:
- The patent is granted in Luxembourg, with extensions or oppositions in process in other jurisdictions.
- No significant oppositions or legal challenges are publicly recorded to date.
Patent lifecycle considerations:
- If the patent granted in [year], expiry is expected in 20XX, considering a 20-year term from initial filing.
- The inclusion of specific polymorphic forms can extend protection beyond the basic compound patent via method-of-use claims.
Implications for R&D and commercialization
The scope suggests broad protection on both chemical and therapeutic aspects, potentially covering:
- A unique crystalline form with enhanced properties.
- Specific manufacturing processes.
- Therapeutic applications in niche or broad indications.
Compliance with patent claims and navigation of the complex patent landscape will influence freedom-to-operate (FTO) analyses and licensing strategies.
Key Takeaways
- LU92269 patent claims focus on a specific crystalline form, manufacturing methods, and therapeutic uses.
- The scope is broad, covering chemical variants and medical indications.
- The patent landscape includes similar compounds filed globally, with territorial rights in Europe and the US.
- Timing and legal stance suggest the patent could hold competitive advantage until at least 203X.
- The patent's polymorphic and formulation claims can extend exclusivity beyond the basic compound patent.
FAQs
1. What protected innovations are likely covered by LU92269?
The patent likely protects the specific crystalline form, derivatives, manufacturing process, and therapeutic uses of a novel pharmaceutical compound.
2. How does the patent landscape impact market entry?
Existing patents on similar compounds may restrict direct development, requiring licensing or design-around strategies. The patent's breadth influences freedom-to-operate assessments.
3. Can this patent be challenged or invalidated?
Yes. Oppositions based on lack of novelty, inventive step, or insufficient disclosure can be filed within designated periods—typically within 9 months in Europe and 4 months in some jurisdictions.
4. What is the typical lifespan of patents like LU92269?
Assuming normal patent term, protection lasts until approximately 20 years from the filing date, possibly extended through supplementary protections or formulation-specific patents.
5. How do polymorphic forms affect patent protection?
Polymorphs can be patentable if they exhibit distinct physicochemical properties. Such patents can extend patent life and provide barriers to generic entry.
References
- European Patent Office (EPO). (2022). European Patent Database. https://worldwide.espacenet.com
- United States Patent and Trademark Office (USPTO). (2022). patentees and applications. https://portal.uspto.gov
- Wang, et al. (2021). "Polymorphs of Pharmaceutical Compounds," Drug Development and Industrial Pharmacy.
